HOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/11/22
HOOKIPA Pharma Reports Second Quarter 2022 Financial Results and Corporate UpdatesGlobeNewsWire • 08/11/22
HOOKIPA Pharma to Report Second Quarter 2022 Financial Results on August 11, 2022GlobeNewsWire • 08/04/22
FDA accepts HOOKIPA's Investigational New Drug Application for HB-300 for the treatment of metastatic castration-resistant prostate cancerGlobeNewsWire • 07/25/22
HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCOGlobeNewsWire • 06/05/22
Preclinical Data on Novel Arenaviral HIV Therapeutic Vaccines Presented at Keystone SymposiumGlobeNewsWire • 06/03/22
HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCOGlobeNewsWire • 05/26/22
HOOKIPA Pharma Reports First Quarter 2022 Financial Results and Recent HighlightsGlobeNewsWire • 05/16/22
HOOKIPA Pharma to Report First Quarter 2022 Financial Results on May 16, 2022GlobeNewsWire • 05/09/22
New data show HOOKIPA's arenaviral immunotherapies induce potent T cell responses in novel combinations and against tumor self-antigensGlobeNewsWire • 04/13/22
HOOKIPA Pharma Inc. (HOOK) CEO Joern Aldag on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/24/22
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 03/24/22
HOOKIPA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 OutlookGlobeNewsWire • 03/24/22
HOOKIPA Announces Promotion of Klaus Orlinger, Ph.D. to Chief Scientific OfficerGlobeNewsWire • 03/22/22
HOOKIPA Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 24, 2022GlobeNewsWire • 03/17/22
Analysts Estimate HOOKIPA Pharma Inc. (HOOK) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 03/10/22
HOOKIPA to present new preclinical, translational, and clinical biomarker data at AACR further supporting the potential of arenaviral platform in oncologyGlobeNewsWire • 03/08/22